Direct MYD88<sup>L265P</sup> gene detection for diffuse large B-cell lymphoma (DLBCL) <i>via</i> a miniaturised CRISPR/dCas9-based sensing chip-Reference-Cited by-同舟云学术

Direct MYD88^L265P gene detection for diffuse large B-cell lymphoma (DLBCL) via a miniaturised CRISPR/dCas9-based sensing chip

Published:2022 Issue:4 Volume:22 Page:768-776
ISSN:1473-0197
Container-title:Lab on a Chip
language:en
Short-container-title:Lab Chip

Author:

Sun Weihan¹²,Guo Wei³,Liu Zhiyi²,Qiao Sennan²,Wang Ziming¹,Wang Jiayu²,Qu Lingxuan²,Shan Liang¹,Sun Fei¹²^ORCID,Xu Shuping⁴^ORCID,Bai Ou³^ORCID,Liang Chongyang¹²^ORCID

Affiliation:

1. Department of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, 1266 Fujin Road, 130021 Changchun, China

2. Institute of Frontier Medical Science, Jilin University, 1163 Xinmin Street, 130021 Changchun, China

3. Department of Hematology, The First Hospital of Jilin University, Jilin University, 71 Xinmin Street, 130021 Changchun, China

4. State Key Laboratory of Supramolecular Structure and Materials, Institute of Theoretical Chemistry, College of Chemistry, Jilin University, 2699 Qianjin Ave., 130012 Changchun, China

Abstract

CRISPR/dCas9 technology integrated with electrochemical detection was developed for ultrasensitive and fast gene mutation detection of diffuse large B-cell lymphoma above a dCas9/sgRNA modified porous anodised aluminium sensing chip.

Funder

People's Government of Jilin Province

Jilin University

Publisher

Royal Society of Chemistry (RSC)

Subject

Biomedical Engineering,General Chemistry,Biochemistry,Bioengineering

Link

http://pubs.rsc.org/en/content/articlepdf/2022/LC/D1LC01055G

Reference40 articles.

1. Oncogenically active MYD88 mutations in human lymphoma

2. Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice